摘要
目的:探讨用乌司他丁腹腔灌洗疗法对重症急性胰腺炎患者进行治疗的临床效果。方法:选取2011年1月~2014年1月我院收治的120例重症急性胰腺炎患者作为研究对象。随机将这120例患者分为观察组和对照组,每组各60例患者。对两组患者均进行常规治疗。在此基础上,为观察组患者使用乌司他丁进行腹腔灌洗治疗,为对照组患者使用乌司他丁进行静脉滴注。然后,对比分析两组患者治疗的效果、APACHEⅡ评分及血清中各项炎性因子的水平。结果 :观察组患者治疗的总有效率为96.7%,对照组患者治疗的总有效率为81.7%。观察组患者治疗的总有效率明显高于对照组患者,差异显著(P<0.05),有统计学意义。治疗后观察组患者的APACHEⅡ评分明显低于对照组患者,差异显著(P<0.05),有统计学意义。治疗后观察组血清中各项炎性因子的水平均明显低于对照组患者,差异显著(P<0.05),有统计学意义。结论 :采用乌司他丁腹腔灌洗疗法对重症急性胰腺炎患者进行治疗,可明显降低其血清中炎性因子的水平,缓解其临床症状。此法值得在临床上推广应用。
Objective: To explore and discuss the impacts of Ulinastatin peritoneal lavage on inflammatory factors and clinical effects of patients with SAP. Method: 120 cases of patients with SAP from January 2011 to January 2014 in our hospital were selected and divided into observation group and control group, with 60 cases in each group. Patients in both groups were given basic therapy, including fasting, gastrointestinal decompression, anti-infection, water and electrolyte balance, and nutritional support. On this basis, the observation group was given Ulinastatin peritoneal lavage, and the control group was given Ulinastatin intravenous drug use. Result: There were 32 cured cases, 17 significant improvement cases, and 9 improvement cases, with total effective rate of 96.7% in the observation group; There were 21 cured cases, 15 significant improvement cases, and 13 improvement cases, with total effective rate of 81.7% in the control group; The effective rate of the observation group was significantly higher than the control group. The difference was statistically significant (P <0.05).Before treatment, there was no significant difference in APACHE II scores between the two groups (P> 0.05); after treatment, the APACHE II score of the observation group was significantly lower than the control group. The difference was significant (P <0.05). Before treatment, the serum CRP, TNF-a, IL-10, IL-15 levels between the two groups showed no significant difference (P> 0.05),After treatment, the above inflammatory factors of the observation group were lower than the control group, with statistically significant difference (P <0.05). Conclusion: Using Ulinastatin peritoneal lavage on the treatment of patients with SAP can significantly reduce the inflammatory factors levels of serum; relieve symptoms and signs, with reliable effects, which is worth clinical promotion.
